Takeda psoriasis drug shows skin clearance in Phase 3 trials

July 16, 2026 6:00 PM

Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) announced secondary endpoint data from two Phase 3 studies of zasocitinib, an investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found